Outcome of Board Meeting
Jubilant Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 29, 2015, inter alia, the following decisions have been taken:- The Board has accorded approval for raising funds through issue of Equity / GDRs / ADRs / FCCBs or other equity related instruments upto an amount of USD 200 million [Rs. 1300 crores (approx.)], subject to approval of the shareholders of the Company and other necessary approvals. Announces Q2 results, Limited Review Report, Results Press Release & Presentation for the Quarter ended September 30, 2015
Jubilant Life Sciences Ltd has announced the following results for the quarter ended September 30, 2015:The Un-Audited Standalone results for the Quarter ended September 30, 2015The Company has posted a net profit of Rs. 509.10 million for the quarter ended September 30, 2015 where as the same was at Rs. 2167.60 million for the quarter ended September 30, 2014. Total Income is Rs. 7458.90 million for the quarter ended September 30,... Disclosure under Regulation 3(12) of SEBI (Share Based Employee Benefit) Regulations, 2014
Jubilant Life Sciences Ltd has informed BSE that the Jubilant Employees Welfare Trust (the "Trust") had un-appropriated inventory of 29,65,766 equity shares of the Company of Re. 1 each as on October 28, 2014 which was not backed by grant of options.Further, as per the provisions of Jubilant Employees Stock Option Plan 2005 ("Plan 2005") read with the Scheme of Amalgamation and Demerger between the Company, Speciality Molecules Limited, Pace... Board Meeting on Oct 29, 2015
Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 29, 2015, inter alia, to consider the proposal to issue securities which may include equity shares and/or instruments or securities convertible into, exchangeable with or otherwise linked to the equity shares of the Company, up to an amount of USD 200 million or Rs. 1300 crores approx. Q2 results on Oct 29, 2015
Jubilant Life Sciences Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on October 29, 2015, inter-alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2015 (Q2).Further, as per the Companys Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company would remain closed for the Designated... Jubilant Life Sciences gets USFDA nod for generic version of Maxalt-MLT
The medicine is the generic version of Maxalt-MLT orally-disintegrating, 5 mg and 10 mg tablets of Merck. Jubilant Life Sciences receives ANDA approval for Rizatriptan Benzoate OD Tablets
Jubilant Life Sciences Ltd has submitted to BSE a copy of Press Release dated October 20, 2015 titled "Jubilant Life Sciences receives ANDA approval for Rizatriptan Benzoate OD Tablets". Jubilant Life Sciences receives ANDA approval for Memantine Hydrochloride Tablets
Jubilant Life Sciences Ltd has submitted to BSE a copy of Press Release dated October 14, 2015 titled "Jubilant Life Sciences receives ANDA approval for Memantine Hydrochloride Tablets". Shareholding Pattern for September 30, 2015
Jubilant Life Sciences Ltd has informed BSE about the Shareholding Pattern as on September 30, 2015. Jubilant Life gets USFDA nod for Indomethacin capsules
Shares of the company were trading at Rs 398.55 apiece, up 0.48%, from the previous close on the BSE